Research output per year
Research output per year
Personal profile
Fellowship & awards
2015 Galenus research prize
2014 Huizinga penning of the Dutch Association of Hospital Pharmacists
Side activities
2002 - 2021 : Member of the Medical Ethical Committee of Netherlands Cancer Institute
2003 - : Involved in many early clinical trials of novel anticancer agents (not further specified, revenues for Netherlands Cancer Institute, Princess Máxima Center or University Medical Center Utrecht)
2016 - 2018: Member of scientific councel "Stichting Kinderen Kankervrij (KiKa)"
2017 - 2021 : Member of the working group Oncology & Hematology of "Horizonscan geneesmiddelen", ZorgInstituut Nederland
2018 - 2023: Board member of Dutch Society of Clinical Pharmacology & Biopharmaceutics
2021 - 2022: Member of the external evaluation committee of 10 year program "Goed Geneesmiddelen Gebruik"
Side activities
2023 - : Member of the working party for the "Kennisagenda 2.0" of the Dutch Association of Hospital Pharmacists
2023 -: Member of the "Concilium" of the Dutch Association of Hospital Pharmacists
Education/Academic qualification
Pharmacy, Utrecht University
1 Sept 1990 → 30 Apr 1997
Award Date: 30 Apr 1997
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Development and validation of ultra-performance liquid chromatography tandem mass spectrometry methods for the quantitative analysis of the antiparasitic drug DNDI-6148 in human plasma and various mouse biomatrices
Schouten, W. M., Van Bocxlaer, K., Rosing, H., Huitema, A. D. R., Beijnen, J. H., Kratz, J. M., Mowbray, C. E. & Dorlo, T. P. C., 1 Jan 2025, In: Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 1250, 124377.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile1 Downloads (Pure) -
Adherence to low-dose methotrexate in children with juvenile idiopathic arthritis using a sensitive methotrexate assay
Möhlmann, J. E., de Roock, S., Egas, A. C., Weijden, E. T., Doeleman, M. J. H., Huitema, A. D. R., van Luin, M. & Swart, J. F., 7 May 2024, In: Pediatric rheumatology online journal. 22, 1, 52.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile -
A joint model of longitudinal pharmacokinetic and time-to-event data to study exposure-response relationships: a proof-of-concept study with alectinib
Lin, L., van der Noort, V., Steeghs, N., Ruiter, G., Beijnen, J. H. & Huitema, A. D. R., Sept 2024, In: Cancer Chemotherapy and Pharmacology. 94, 3, p. 453-459 7 p.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile -
A multiplex UPLC-MS/MS method for the quantification of three PD-L1 checkpoint inhibitors, atezolizumab, avelumab, and durvalumab, in human serum
Buitelaar, P. L. M., de Jong, K. A. M., Aardenburg, L., van der Heijden, M. S., Huitema, A. D. R., Beijnen, J. H. & Rosing, H., 15 Jun 2024, In: Journal of Pharmaceutical and Biomedical Analysis. 243, 9 p., 116108.Research output: Contribution to journal › Article › Academic › peer-review
-
Analytical Validation of a Volumetric Absorptive Microsampling Method for Therapeutic Drug Monitoring of the Oral Targeted Anticancer Agents, Abiraterone, Alectinib, Cabozantinib, Imatinib, Olaparib, and Sunitinib, and Metabolites
Meertens, M., de Vries, N., Rosing, H., Steeghs, N., Beijnen, J. H. & Huitema, A. D. R., Aug 2024, In: Therapeutic drug monitoring. 46, 4, p. 494-502 9 p.Research output: Contribution to journal › Article › Academic › peer-review